Xconomy: Westphal Leaving Glaxo, Cubist Settles Patent Litigation with Teva, BSX Buys S.I., & More Boston-Area Life Sciences News
Summary
Westphal Leaving Glaxo, Cubist Settles Patent Litigation with Teva, BSX Buys S.I., & More Boston-Area Life Sciences News Xconomy Boston — We saw news of personnel shifts, litigation, clinical progress, financing, and acquisitions from health IT firms, device makers, and drug companies in New England this week.—GlaxoSmithKline (NSYE: GSK) announced Boston-based biotech entrepreneur and investor Christoph Westphal will leave his position at SR One, Glaxo’s venture arm.Both Dipp and Westphal came to Glaxo through the drug firm’s $720 million acquisition of Sirtris Pharmaceuticals in 2008, and both have agreed to stay in their positions until successors are lined up.—Natick, MA-medical devices maker Boston Scientific (NASDAQ: BSX) paid $5.13 million upfront for acquiring Israel-based S.I.Boston Scientific could pay a total of $24.3 million if S.I., a maker of catheter devices for treating artery blockages, hits certain milestones.
Classifications
AskAI Classifications
LabelsLinked Companies
